Expertise in
25
conditions

Dr. Michael Gold

Dermatology
Gold Skin Care Center PLC
2000 Richard Jones Rd, 
Nashville, TN 
Referral may be required
Expertise in
25
conditions
Gold Skin Care Center PLC
2000 Richard Jones Rd, 
Nashville, TN 

Overview

Michael Gold is a Dermatologist practicing medicine in Nashville, Tennessee.

Dr. Gold is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Acne, Keloids, Athlete's Foot, and Comedones.

He is actively involved in clinical research, co-authoring 446 peer reviewed articles and participating in 10 clinical trials.

Specialties

Dermatology

Licenses

Specialist in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Gold Skin Care Center PLC
2000 Richard Jones Rd, Nashville, TN 37215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Feasibility Study to Evaluate Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
A Feasibility Study to Evaluate Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug, Other
Study Drug: STP705
Study Phase: Phase 2
A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel® Deep Lidocaine Versus Juvederm® Ultra Plus in the Treatment of Moderate to Severe Facial Wrinkles and Folds
A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel® Deep Lidocaine Versus Juvederm® Ultra Plus in the Treatment of Moderate to Severe Facial Wrinkles and Folds
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (With Lidocaine) Versus Revanesse® Ultra for the Correction of Nasolabial Folds (NLF)
A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (With Lidocaine) Versus Revanesse® Ultra for the Correction of Nasolabial Folds (NLF)
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Device
Study Phase: Not Applicable
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Enrollment Status: Completed
Publish Date: October 20, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

446 Total Publications

Oral Versus Injectable Therapies in Psoriasis: Beyond Route to Molecular Modality and Pharmacologic Determinants.
Oral Versus Injectable Therapies in Psoriasis: Beyond Route to Molecular Modality and Pharmacologic Determinants.
Journal: International journal of dermatology
Published: April 04, 2026
Similar Doctors
Expertise in
78
conditions
Dr. Sara Kantrow
Dermatology
Expertise in
78
conditions
Dr. Sara Kantrow
Dermatology
Referral may be required

Nashville Skin And Cancer PLC.

2301 21st Ave S, 
Nashville, TN 
 (1.7 miles away)
615-327-9797
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sara Kantrow is a Dermatologist practicing medicine in Nashville, Tennessee. Dr. Kantrow is highly rated in 78 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Pustules, Syringoma, and Sebaceous Adenoma.

Expertise in
9
conditions
Dr. John Zic
Dermatology
Expertise in
9
conditions
Dr. John Zic
Dermatology
Referral may be required

Vanderbilt Dermatopathology

719 Thompson Ln Ste 26300, 
Nashville, TN 
 (2.0 miles away)
615-322-6485
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Zic is a Dermatologist practicing medicine in Nashville, Tennessee. Dr. Zic is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.

Expertise in
83
conditions
Dr. Alan Boyd
Dermatology
Expertise in
83
conditions
Dr. Alan Boyd
Dermatology
Referral may be required

Vanderbilt Dermatopathology

719 Thompson Ln Ste 26300, 
Nashville, TN 
 (2.0 miles away)
615-322-6485
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Boyd is a Dermatologist practicing medicine in Nashville, Tennessee. Dr. Boyd is highly rated in 83 conditions, according to our data. His clinical expertise encompasses Muir-Torre Syndrome, Basal Cell Skin Cancer, Actinic Keratosis, and Hyperkeratosis Lenticularis Perstans.

Frequently Asked Questions about Dr. Michael Gold

How do I make an appointment with Dr. Michael Gold?

You can book an appointment with Dr. Michael Gold by calling their office at 615-383-2400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Gold a top-rated expert for Acne?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Gold is classified as an Elite expert for Acne, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Gold specialize in?

While Dr. Michael Gold is a Dermatology, they have specific expertise in Acne, Keloids, and Athlete's Foot. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Michael Gold participate in research or clinical trials?

Yes. Dr. Michael Gold has published 446 articles and abstracts on conditions like Acne. You can view a list of Dr. Michael Gold's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael Gold accept my insurance?

Dr. Michael Gold accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 615-383-2400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile